A Predictive Model for the Development of Hormone-Responsive Breast Cancer

Gorla, S.; Hou, Nanjiang; Acharya, Simbi; Rademaker, Alfred; Khan, Seema A.; Staradub, Valerie L.; Morrow, Monica

doi:10.1007/s10434-004-1170-4

Ann Surg Oncol

2004

DOI: 10.1007/s10434-004-1170-4

|View full text |Cite

A Predictive Model for the Development of Hormone-Responsive Breast Cancer

S. Gorla

Nanjiang Hou

Simbi Acharya

et al.

Abstract: Our findings, if prospectively validated, may help identify those who would obtain the greatest benefit from hormonal chemoprevention strategies for breast cancer risk reduction.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Arzoxifene: the development and clinical outcome of an ideal SERM

Münster

2006

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Hormone-sensitive tumours are among the most common cancers in women. Specific inhibition of the estrogen receptor by selective estrogen receptor downregulators or selective estrogen receptor modulators (SERMs) is effective for the treatment of breast and endometrial cancers and may be used for the prevention of breast cancer. Due to differential recruitment of co-activators and corepressors, SERMs are tissue specific and may have antiestrogenic effects in some tissues, with estrogen agonist activity in others. The ideal SERM would have antiestrogenic effects on the breast and endometrium, but pro-estrogenic effects on bone and lipids. The SERM, arzoxifene (LY-353381.HCl) meets all of these criteria. This review summarises the development, preclinical studies and the clinical outcome of arzoxifene and places it in context with other modalities in the treatment of hormone receptor-positive tumours.

show abstract

Arzoxifene: the development and clinical outcome of an ideal SERM

Münster

2006

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A Predictive Model for the Development of Hormone-Responsive Breast Cancer

Abstract: Our findings, if prospectively validated, may help identify those who would obtain the greatest benefit from hormonal chemoprevention strategies for breast cancer risk reduction.

Cited by 1 publication

References 45 publications

Arzoxifene: the development and clinical outcome of an ideal SERM

Arzoxifene: the development and clinical outcome of an ideal SERM

Contact Info

Product

Resources

About